Bioventix Share Discussion Threads

[strollingmolby] 08/12/2023 18:05

There is a brief mention of BVXP in The Motley Fool today - may have created some buying volume.

[strollingmolby] 08/12/2023 17:55

Ah, £40 - hello old friend!

[suetballs] 20/11/2023 08:43

With a positive effect on the share price Makes a change atm.
Suet

[melody9999] 19/11/2023 23:33

nice piece in the Times

[toptrump1] 19/11/2023 23:17

Where’s this business heading? Troponin was supposed to be the one to replace vitd

[stepone68] 09/11/2023 09:53

Ex-div for 90p this morning hence the drop.

[levr] 09/11/2023 08:40

This story is being reported by the mainstream press to-day:

www.alzheimersresearchuk.org/a-five-year-project-to-bring-alzheimers-blood-tests-to-the-nhs/

"A range of blood tests for Alzheimer’s are currently in the research stages, including those looking for specific proteins, such as amyloid and tau, that occur before dementia symptoms appear. But no test is currently clinically validated in the UK, or available to patients in the NHS."

[melody9999] 02/11/2023 08:05

forced redemption eeza....no reflection on BVXP

[eeza] 01/11/2023 16:57

Nortrust reduced 0.5%

[stepone68] 01/11/2023 11:02

I got a response from Peter, which basically just confirmed that payments will end in 2032 but he did also mention that this was a historic contract and that they have newer contracts which are perpetual, which relates to another point someone raised above.

Cheers,
StepOne

[gnnmartin] 31/10/2023 12:15

I assume Siemens will (and perhaps already does) make the antibody themselves. BVXP are paid a royalty, not a 'cost of antibody', IYSWIM.

[levr] 31/10/2023 12:07

My assumption is payments will cease under the terms of the contract, viz. Bioventix were paid to do part of the development work for limited reward. Development is a one-off activity, so what is there to renew/extend?

[stepone68] 31/10/2023 12:03

Well, I knew I had emailed the company before, and had a reply from Peter Harrison, so I searched my emails, and it turns out that 2 years ago I had sent him an almost identical question after having read about the contract end date in Maynard Payton's blog. At the time all he did was confirm that payments would cease in 2032, so I have gone back to ask him again whether there would be any possibility of a contract extension.

Will let you know if he says anything more.

Cheers,
StepOne

[stepone68] 31/10/2023 11:54

Hi alter ego, I will definitely email investor relations, but would also like input from here if possible.

LevR - I read all that. What am asking is, why will payments cease in 2032. I realise the contract runs out then, but contracts are renewed or extended all the time. Why do they say in the results 'payments will cease' in 2032. There must be more to it than that.

Thanks
StepOne

[levr] 31/10/2023 10:53

From the results:
"Bioventix adopts one of two commercial approaches when creating new antibodies. The first is own-risk antibody creation projects which gives Bioventix the complete freedom to commercialise the antibodies produced. The second is contract antibody creation projects in partnership with customers who supply materials, know-how and funding and to create antibodies that can only be commercialised with the partner company." .. "until June 2032 when contractual payments from our contract with Siemens will cease."

Bioventix's business model is to undertake a mixture of contract work and own-risk development. Troponin is the former.

[alter ego] 31/10/2023 10:12

stepone68, maybe you should ask the company for a definitive answer.

[stepone68] 31/10/2023 09:50

What do people think about Siemens payments ending in 2032. Does that mean that after 2032, Siemens will not be doing any more Troponin testing, or does it mean that someone else will be supplying antibodies, or will Siemens be manufacturing their own, royalty-free?

In most businesses a 10 year supply contract would be seen as a great result, and I'd be assuming a decent chance of renewal or extension at some point, but the way the release is written, they are saying that money is definitely going to stop.

Any views?
Thanks,
StepOne

[maddox] 31/10/2023 09:48

If you top-up now at our shorted depressed price you'll be locking in a nice yield of c.4%.

One further point the 2023 dividends of 152p looks to be no change on 2022. However, the 152p paid in 2022 included one of BVXP's regular special dividends of 26p. So, excluding this the dividends increased a very healthy 20.6%!

In the last five years BVXP has paid three Special Dividends - so that 4% is probably understated albeit the corp tax increase will slow cash accumulation.

[gdjs100] 30/10/2023 18:24

Your use of the plural there implies it was more than one share! I wouldn't be so sure!

[maddox] 30/10/2023 18:19

I wonder who leant Michael the shares?

[toptrump1] 30/10/2023 18:14

74tom why don’t you contact the CEO, troponin revenue could treble next yr. don’t place too much reliance on broker forecasts.

[maddox] 30/10/2023 18:10

I remember seeing an RNS from Norges Bank that had leant a tranch of shares. This explained the dip in the firm's share price - only to see the share price rebound strongly.... followed by another RNS from Norges Bank that had increased their holding. Presumably, they had picked up the shorters shares at a lower price and been paid for the privilege.

[maddox] 30/10/2023 18:02

It's self disclosed and he doesn't mention position size. If you follow him closely you might be able to guess.

hxxps://x.com/shiftingshares/status/1718935311089045906?s=12&t=bJYOlk0mMg95lYX3IIuXew